ArticleAdvances in therapy2024

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data.

Nazia Chaudhuri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.